Filing Flows › DarioHealth (DRIO) › R&D spending
DarioHealth (DRIO) R&D spending by quarter
DarioHealth's R&D spending was $2.1M in Q2 2026 (second quarter 2026), -12% from Q1 2026. Over the last 7 quarters it ranged from $2.1M (Q2 2026) to $5.3M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.1M | -12% | -44% |
| Q1 2026 | $2.4M | -9% | -42% |
| Q4 2025 | $2.6M | -21% | -50% |
| Q3 2025 | $3.3M | -11% | — |
| Q2 2025 | $3.7M | -9% | — |
| Q1 2025 | $4.1M | -22% | — |
| Q4 2024 | $5.3M | — | — |
Q2 2026 at a glance
DarioHealth, Q2 2026: revenue $5.2M (-4% year over year), operating margin -125.1%, net loss $7.9M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is DarioHealth's R&D spending?
DarioHealth's R&D spending was $2.1M in Q2 2026 (second quarter 2026), -12% from Q1 2026.
How has DarioHealth's R&D spending changed?
Over the last 7 quarters it ranged from $2.1M (Q2 2026) to $5.3M (Q4 2024).